Key Takeaways
- Nephrology, a target for drug discovery and development is enjoying a renaissance, evidenced by growth in renal disease clinical trials, pipeline assets, and publications over the last five years.
- The current momentum in clinical activity in nephrology is driven by the increasing societal and economic burden of chronic kidney disease (CKD) and other renal conditions, as well as key scientific advances improving research feasibility, including discovery of new drug targets and availability of new modalities.
- The approvals of Farxiga and Kerendia to address CKD, numerous licensing deals, and large financing rounds for nephrology focused companies, highlight the tangible results of this renewed focus on renal diseases